Please assess the completion status of the following clinical trial:

Trial Title: The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Alzheimer-type dementia according to the definition of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV-TR) and a diagnosis of possible or probable Alzheimer-type dementia, according to NINCDS-ADRDA classification (American Psychiatric Association, 2000~* McKhann, G. et al, 1984)~* should have moderate dementia, evidenced by a Mini-Mental Status examination (MMSE) score between 12 and 20, including these limits~* At inclusion, a recent CT or MRI must be available~* Physical examination and the electrocardiogram (ECG) performed at the screening visit must be normal or consistent with the underlying illness in the study population~* History of sleep behavior changes (eg: insomnia, daytime sleepiness, changes in sleep/wakefulness cycle) 2 or more weeks before, reported by the caregiver~* Patients should have a caregiver sufficiently informed of their condition and, if possible, living with them~* Patients (or their legally-acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study~Exclusion Criteria:~* History of other neurodegenerative disorders, such as Parkinson's disease, Pick disease or Huntington's chorea, Down syndrome, Creutzfeldt-Jakob disease (patients with mild extrapyramidal signs for which no treatment is required are not excluded from the trial)~* Clinically significant cardiovascular disease expected to limit the ability of the patient to participate and complete the study~* Any history of epilepsy or seizures (except for febrile seizures in childhood)~* Clinically significant psychiatric condition, according to the DSM-IV criteria, particularly major depression or schizophrenia currently~* Active peptic ulcer (treatment of the disease started \< 3 months or treatment is not successful~* Clinically significant liver, renal, pulmonary, metabolic, or endocrine disorders~* Clinically significant urinary flow obstruction~* History of or suspected alcoholism or drug abuse in accordance to the DSM-IV criteria, in the past year, or previous history of prolonged abuse~* Previous therapy with memantine or an acetylcholinesterase inhibitor (including galantamine)~* Patients receiving antipsychotics, hypnotic or sedative agents (those patients who need this kind of medication during the study would be withdrawn from the study and replaced)~* Bedridden patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Galantamine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).